Ambroxol study for Gaucher disease and Parkinson symptoms
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial looks at ambroxol, a medicine, for people who have Gaucher disease and Parkinson disease that is linked to Gaucher. If you fit the condition group, the study may help doctors learn whether ambroxol can improve Parkinson-related symptoms in this specific situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Gaucher disease (types 1, 2, or 3).
- You have Parkinson disease that is related to GBA (Gaucher)
- You must be able to join a medication study for your condition
- There are no stated extra exclusion limits in the listed criteria
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether ambroxol (or a placebo) can slow the progression of Parkinson’s disease. It may help by aiming to change how the disease develops over time.
This study looks at how standard treatments for Gaucher disease affect lung problems, bone damage, and parkinson-like symptoms. It aims to find better ways to treat these complications and improve quality of life.
This trial tests a remote way to assess people newly diagnosed with Parkinson's disease, to help monitor their condition and guide care.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This registry collects information about people with Parkinson’s who have specific changes in the GBA gene. The goal is to better understand how these gene changes affect Parkinson’s and support future research.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
Hear when a new Gaucher Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.